Non-small cell lung cancer in China

Area of Science:

• Oncology
• Pulmonology
• Cancer Research

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), presents a significant health challenge in China with high incidence and mortality.
• Early-stage NSCLC often lacks distinct clinical symptoms, leading to delayed diagnosis and missed treatment opportunities.
• Risk factors include tobacco use, family history, radiation, and chronic lung diseases.

Purpose of the Study:

• To review recent advancements in non-small cell lung cancer (NSCLC) in China.
• To cover epidemiology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.
• To highlight progress in early detection and treatment strategies.

Main Methods:

• Literature review of recent studies and clinical guidelines on NSCLC in China.
• Synthesis of information on epidemiological trends and risk factors.
• Analysis of developments in molecular carcinogenesis, targeted therapy, and immunotherapy.

Main Results:

• Nationwide screening programs enhance early NSCLC detection and survival rates in China.
• Targeted therapies, driven by oncogenic drivers, prolong survival for NSCLC patients.
• Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are standard for advanced NSCLC, with immunotherapy integrated into various treatment stages.

Conclusions:

• Significant progress has been made in understanding and treating NSCLC in China.
• Screening, targeted therapy, and immunotherapy are crucial for improving patient outcomes.
• Ongoing research and guideline updates reflect the evolving landscape of NSCLC management.